Patents by Inventor Katsuhiko Iseki
Katsuhiko Iseki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240110186Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 . . . (I) and Lx2-X—Y-Ly-Yc-3? . . . (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.Type: ApplicationFiled: September 1, 2023Publication date: April 4, 2024Inventors: Kyohei Koshimoto, Katsuhiko Iseki, Hideaki Inada, Tatsuya Fujita, Keiichi Okimura, Munetaka Kunishima, Tadaaki Ohgi, Eriko Aoki
-
Patent number: 11920131Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, the method including: (i) an annealing step of annealing a first single-stranded oligoRNA molecule and a second single-stranded oligoRNA molecule; and (ii) a ligation step of ligating 3? end of the first single-stranded oligoRNA molecule and 5? end of the second single-stranded oligoRNA molecule by an Rnl2 family ligase, wherein a sequence produced by ligating the first single-stranded oligoRNA molecule and the second single-stranded oligoRNA molecule includes a gene expression-inhibiting sequence for the target gene.Type: GrantFiled: March 29, 2019Date of Patent: March 5, 2024Assignee: Toray Industries, Inc.Inventors: Hideaki Inada, Katsuhiko Iseki, Keiichi Okimura, Masato Sanosaka, Ayumi Takashina
-
Patent number: 11891602Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 (I) and Lx2-X—Y-Ly-Yc-3? (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.Type: GrantFiled: October 2, 2019Date of Patent: February 6, 2024Assignee: Toray Industries, Inc.Inventors: Kyohei Koshimoto, Katsuhiko Iseki, Hideaki Inada, Tatsuya Fujita, Keiichi Okimura, Munetaka Kunishima, Tadaaki Ohgi, Eriko Aoki
-
Patent number: 11834431Abstract: A crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having peaks at diffraction angles 2?)(° of 12.6±0.2, 16.0±0.2, 17.7±0.2, 18.5±0.2, and 21.3±0.2 in powder X-ray diffraction; and the crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperi din-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having an endothermic peak at 173° C. to 177° C. in simultaneous thermogravimetric-differential thermal analysis.Type: GrantFiled: February 10, 2021Date of Patent: December 5, 2023Assignee: Toray Industries, Inc.Inventors: Hirozumi Takahashi, Yoko Baba, Yasuhiro Morita, Katsuhiko Iseki, Naoki Izumimoto
-
Publication number: 20210317495Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 (I) and Lx2-X—Y-Ly-Yc-3? (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.Type: ApplicationFiled: October 2, 2019Publication date: October 14, 2021Inventors: Kyohei Koshimoto, Katsuhiko Iseki, Hideaki Inada, Tatsuya Fujita, Keiichi Okimura, Munetaka Kunishima, Tadaaki Ohgi, Eriko Aoki
-
Publication number: 20210198236Abstract: A crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having peaks at diffraction angles 2? (°) of 12.6±0.2, 16.0±0.2, 17.7±0.2, 18.5±0.2, and 21.3±0.2 in powder X-ray diffraction; and the crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having an endothermic peak at 173° C. to 177° C. in simultaneous thermogravimetric-differential thermal analysis.Type: ApplicationFiled: February 10, 2021Publication date: July 1, 2021Inventors: Hirozumi Takahashi, Yoko Baba, Yasuhiro Morita, Katsuhiko Iseki, Naoki Izumimoto
-
Patent number: 10961217Abstract: Crystals of a compound that exhibits an analgesic action against neuropathic pain and/or fibromyalgia syndrome are useful as pharmaceuticals. The crystals may be of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one or a pharmacologically acceptable salt thereof.Type: GrantFiled: August 25, 2017Date of Patent: March 30, 2021Assignee: Toray Industries, Inc.Inventors: Hirozumi Takahashi, Yoko Baba, Yasuhiro Morita, Katsuhiko Iseki, Naoki Izumimoto
-
Publication number: 20210024930Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, the method including: (i) an annealing step of annealing a first single-stranded oligoRNA molecule and a second single-stranded oligoRNA molecule; and (ii) a ligation step of ligating 3? end of the first single-stranded oligoRNA molecule and 5? end of the second single-stranded oligoRNA molecule by an Rnl2 family ligase, wherein a sequence produced by ligating the first single-stranded oligoRNA molecule and the second single-stranded oligoRNA molecule includes a gene expression-inhibiting sequence for the target gene.Type: ApplicationFiled: March 29, 2019Publication date: January 28, 2021Inventors: Hideaki Inada, Katsuhiko Iseki, Keiichi Okimura, Masato Sanosaka, Ayumi Takashina
-
Publication number: 20200172507Abstract: Crystals of a compound that exhibits an analgesic action against neuropathic pain and/or fibromyalgia syndrome are useful as pharmaceuticals. The crystals may be of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: August 25, 2017Publication date: June 4, 2020Inventors: Hirozumi Takahashi, Yoko Baba, Yasuhiro Morita, Katsuhiko Iseki, Naoki Izumimoto
-
Patent number: 10253014Abstract: A cyclic amine derivative represented by a general formula (I) or a pharmacologically acceptable salt thereof: wherein n represents 1 or 3, R1 represents an alkyl group having 1 to 6 carbon atoms unsubstituted, substituted with a halogen atom or substituted with an alkyloxy group having 1 to 4 carbon atoms and R2 represents a hydrogen atom or a halogen atom.Type: GrantFiled: March 24, 2016Date of Patent: April 9, 2019Assignee: Toray Industries, Inc.Inventors: Yuji Osada, Naoki Izumimoto, Yasuhiro Morita, Shuji Udagawa, Katsuhiko Iseki, Tomoya Miyoshi, Shunsuke Iwano
-
Patent number: 10173999Abstract: A compound exerts an analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. A cyclic amine derivative represented by the following general formula, or a pharmacologically acceptable salt thereof: Methods using the compound including the cyclic amine derivative or a pharmacologically acceptable salt thereof to treat pain, neuropathic pain and fibromyalgia syndrome.Type: GrantFiled: February 26, 2016Date of Patent: January 8, 2019Assignee: Toray Industries, Inc.Inventors: Tadamasa Arai, Yasuhiro Morita, Shuji Udagawa, Katsuhiko Iseki, Naoki Izumimoto
-
Patent number: 10117853Abstract: A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. A cyclic amine derivative represented by general formula or a pharmacologically acceptable salt thereof: A method of treating neuropathic pain includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal. A method of treating fibromyalgia syndrome includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal.Type: GrantFiled: March 24, 2016Date of Patent: November 6, 2018Assignee: Toray Industries, Inc.Inventors: Shuji Udagawa, Yasuhiro Morita, Naoki Izumimoto, Katsuhiko Iseki, Shunsuke Iwano, Tomoya Miyoshi, Yuji Osada, Tetsuro Koreeda, Masanori Murakami, Motohiro Shiraki, Kei Takahashi, Keiyu Oshida, Eriko Higashi
-
Publication number: 20180104221Abstract: A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. A cyclic amine derivative represented by general formula or a pharmacologically acceptable salt thereof A method of treating neuropathic pain includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal. A method of treating fibromyalgia syndrome includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal.Type: ApplicationFiled: March 24, 2016Publication date: April 19, 2018Inventors: Shuji Udagawa, Yasuhiro Morita, Naoki Izumimoto, Katsuhiko Iseki, Shunsuke Iwano, Tomoya Miyoshi, Yuji Osada, Tetsuro Koreeda, Masanori Murakami, Motohiro Shiraki, Kei Takahashi, Keiyu Oshida, Eriko Higashi
-
Publication number: 20180072701Abstract: A cyclic amine derivative represented by a general formula (I) or a pharmacologically acceptable salt thereof: wherein n represents 1 or 3, R1 represents an alkyl group having 1 to 6 carbon atoms unsubstituted, substituted with a halogen atom or substituted with an alkyloxy group having 1 to 4 carbon atoms and R2 represents a hydrogen atom or a halogen atom.Type: ApplicationFiled: March 24, 2016Publication date: March 15, 2018Inventors: Yuji Osada, Naoki Izumimoto, Yasuhiro Morita, Shuji Udagawa, Katsuhiko Iseki, Tomoya Miyoshi, Shunsuke Iwano
-
Publication number: 20180065950Abstract: A compound exerts an analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. A cyclic amine derivative represented by the following general formula, or a pharmacologically acceptable salt thereof: Methods using the compound including the cyclic amine derivative or a pharmacologically acceptable salt thereof to treat pain, neuropathic pain and fibromyalgia syndrome.Type: ApplicationFiled: February 26, 2016Publication date: March 8, 2018Inventors: Tadamasa Arai, Yasuhiro Morita, Shuji Udagawa, Katsuhiko Iseki, Naoki Izumimoto
-
Patent number: 9505740Abstract: A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The cyclic amine derivative is represented by formula, a prodrug thereof or a pharmacologically acceptable salt thereof: wherein A represents a group represented by Formula (IIa), (IIb) or (IIc): wherein R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R4 represents a hydrogen atom or an alkylcarbonyl group having 2 to 6 carbon atoms or an alkyl group having 1 to 6 carbon atoms and optionally substituted with an alkylcarbonylamino group having 2 to 6 carbon atoms and n represents 1 or 2, in which when R3 and R4 each independently represent an alkyl group having 1 to 6 carbon atoms, R1 represents an alkyl group having 1 to 6 carbon atoms and substituted with a hydroxyl group, an amino group or a carboxyl group.Type: GrantFiled: September 26, 2014Date of Patent: November 29, 2016Inventors: Yasuhiro Morita, Naoki Izumimoto, Katsuhiko Iseki, Shunsuke Iwano, Shuji Udagawa, Tomoya Miyoshi, Yuji Osada, Tetsuro Koreeda, Masanori Murakami, Motohiro Shiraki, Kei Takahashi, Keiyu Oshida
-
Publication number: 20160194302Abstract: A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The cyclic amine derivative is represented by formula, a prodrug thereof or a pharmacologically acceptable salt thereof: wherein A represents a group represented by Formula (IIa), (IIb) or (IIc): wherein R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R4 represents a hydrogen atom or an alkylcarbonyl group having 2 to 6 carbon atoms or an alkyl group having 1 to 6 carbon atoms and optionally substituted with an alkylcarbonylamino group having 2 to 6 carbon atoms and n represents 1 or 2, in which when R3 and R4 each independently represent an alkyl group having 1 to 6 carbon atoms, R1 represents an alkyl group having 1 to 6 carbon atoms and substituted with a hydroxyl group, an amino group or a carboxyl group.Type: ApplicationFiled: September 26, 2014Publication date: July 7, 2016Inventors: Yasuhiro MORITA, Naoki IZUMIMOTO, Katsuhiko ISEKI, Shunsuke IWANO, Shuji UDAGAWA, Tomoya MIYOSHI, Yuji OSADA, Tetsuro KOREEDA, Masanori MURAKAMI, Motohiro SHIRAKI, Kei TAKAHASHI, Keiyu OSHIDA
-
Patent number: 8575175Abstract: The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances.Type: GrantFiled: July 23, 2009Date of Patent: November 5, 2013Assignee: Toray Industries, Inc.Inventors: Fuko Matsuda, Katsuhiko Iseki, Hajimu Kurumatani, Mitsuko Miyamoto
-
Patent number: 8349874Abstract: A method relieves both nociceptive pain and neuropathic pain and has fewer side effects. The compound includes cyclohexane derivatives represented by the following compound, or pharmaceutically acceptable salts thereof or prodrugs thereof.Type: GrantFiled: June 27, 2012Date of Patent: January 8, 2013Assignee: Toray Industries, Inc.Inventors: Yasuhiro Morita, Katsuhiko Iseki, Yuji Sugawara, Hideyuki Tsutsiu, Shunsuke Iwano, Naoki Izumimoto, Tadamasa Arai, Hidetoshi Noda, Chihiro Yoshida
-
Publication number: 20120270906Abstract: A method relieves both nociceptive pain and neuropathic pain and has fewer side effects. The compound includes cyclohexane derivatives represented by the following compound, or pharmaceutically acceptable salts thereof or prodrugs thereof.Type: ApplicationFiled: June 27, 2012Publication date: October 25, 2012Applicant: Toray Industries, Inc.Inventors: Yasuhiro Morita, Katsuhiko Iseki, Yuji Sugawara, Hideyuki Tsutsui, Shunsuke Iwano, Naoki Izumimoto, Tadamasa Arai, Hidetoshi Noda, Chihiro Yoshida